Reflections From Biotech Leader John Maraganore

The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.

Key Takeaways
  • Alnylam and City Therapeutics founder John Maraganore was a featured speaker at Biotech CEO & Investor, and reflected on lessons learned in his career.
  • While the political environment and capital markets remain tumultuous, he said the industry remains resilient.
  • A new US administration could present opportunities to modernize the FDA, he added. 

Biotech leader John Maraganore has had a respected career in the industry, having built Alnylam Pharmaceuticals over 19 years into the leading RNAi therapeutics company in the world with five marketed RNAi medicines

Maraganore stepped down as CEO of Alnylam in 2021, with the company having a $25bn valuation, paving the way for his successor Yvonne Greenstreet. He has since embarked on a new corporate venture, launching the RNAi-based therapeutics company City Therapeutics with a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

More from Conferences

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By 

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.